M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Not Applicable

Recruiting

Conditions: Ovarian Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-10-04

Last Posted Date: 2024-10-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8000

Registration Number: NCT00539162

Locations: 🇺🇸
Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
John Stoddard Cancer Center, Des Moines, Iowa, United States
🇺🇸
Carol G. Simon Cancer Center / Atlantic Health, Morristown, New Jersey, United States

and more 8 locations

Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)

Phase 1

Completed

Conditions: Hyperparathyroidism

Interventions: Drug: Vitamin D
Device: Four-dimensional computed tomography (4DCT)

First Posted Date: 2007-10-03

Last Posted Date: 2019-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT00538720

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: ARA-C
Drug: BCNU
Drug: Campath-1H
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Fludarabine
Drug: Melphalan
Drug: Rituximab
Other: Allogeneic Stem Cell Transplantation
Radiation: Total body radiation (TBI)
Drug: Methotrexate
Drug: Tacrolimus
Procedure: Adback NK or T Cell

First Posted Date: 2007-09-28

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT00536978

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

OraTest in Combination With Visual Examination and Visual Examination Alone

Phase 3

Terminated

Conditions: Head And Neck Cancer
Oropharynx Cancer

Interventions: Other: Visual Examination
Drug: OraTest

First Posted Date: 2007-09-28

Last Posted Date: 2016-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00537199

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

Phase 2

Completed

Conditions: Leukemia
CLL
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Lenalidomide

First Posted Date: 2007-09-26

Last Posted Date: 2018-08-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 61

Registration Number: NCT00535873

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Neuropathic Pain in Survivors of Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-09-26

Last Posted Date: 2015-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 239

Registration Number: NCT00535067

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Weight Gain Prevention for Breast Cancer Survivors

Not Applicable

Conditions: Breast Cancer

Interventions: Behavioral: Weight Gain Prevention Program
Behavioral: Questionnaire

First Posted Date: 2007-09-21

Last Posted Date: 2020-01-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 46

Registration Number: NCT00533338

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: BAY 43-9006
Drug: Paclitaxel
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2007-09-21

Last Posted Date: 2016-02-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00533585

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma

Phase 1

Terminated

Conditions: Neuroblastoma

Interventions: Drug: ZD6474
Drug: Retinoic Acid

First Posted Date: 2007-09-21

Last Posted Date: 2011-12-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00533169

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy

Terminated

Conditions: Malignant Neoplasm

Interventions: Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2007-09-19

Last Posted Date: 2020-01-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT00532064

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy